Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. COSMOS Pharmaceutical's Average Total Inventories for the quarter that ended in May. 2026 was $634 Mil. COSMOS Pharmaceutical's Revenue for the
three
months ended in May. 2026 was $1,829 Mil.
COSMOS Pharmaceutical's Inventory-to-Revenue for the quarter that ended in May. 2026 was 0.35.
COSMOS Pharmaceutical's Inventory-to-Revenue for the quarter that ended in May. 2026
declined
from Feb. 2026 (0.36) to Feb. 2026 (0.35)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
COSMOS Pharmaceutical's Days Inventory for the
three
months ended in May. 2026 was 39.84.
Inventory Turnover measures how fast the company turns over its inventory within a year.
COSMOS Pharmaceutical's Inventory Turnover for the quarter that ended in May. 2026 was 2.29.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
COSMOS Pharmaceutical's Days Inventory for the
three
months ended in May. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Inventory-to-Revenue Related Terms
COSMOS Pharmaceutical Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Inventory-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
COSMOS Pharmaceutical's Inventory-to-Revenue for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Inventory-to-Revenue of 0.35 as of May. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on COSMOS Pharmaceutical and its competitors.
Is COSMOS Pharmaceutical's Inventory-to-Revenue too high?
COSMOS Pharmaceutical's current Inventory-to-Revenue is 0.35. Overall, COSMOS Pharmaceutical has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Inventory-to-Revenue compare to competitors?
COSMOS Pharmaceutical's Inventory-to-Revenue of 0.35 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Healthcare Providers & Services company?
A good Inventory-to-Revenue depends on the Healthcare Providers & Services industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on COSMOS Pharmaceutical and its competitors. COSMOS Pharmaceutical's current Inventory-to-Revenue is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
COSMOS Pharmaceutical (CSMYF) has a current Inventory-to-Revenue of 0.35. The stock's GF Value™ is $48.63, compared to a current price of $37.06 — trading 23.8% below its estimated fair value. The current Inventory-to-Revenue is 0.35. COSMOS Pharmaceutical's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Inventory-to-Revenue is 0.35 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 23.8% below its estimated GF Value™ of $48.63.
Key valuation signals for CSMYF:
Inventory-to-Revenue: 0.35
GF Value™: $48.63 vs. price of $37.06 (23.8% below fair value)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
89GF Score
Get the complete analysis for CSMYF
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
